Cowen & Co.

The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.

The investment bank gave shares of the molecular diagnostics firm an Outperform rating and a price target of $20 per share.

Cowen & Co. upgraded Fluidigm to an Outperform rating, while William Blair upgraded Hologic also to Outperform. 

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded Hologic's stock from Outperform to Market Perform and lowered its price target on the shares.

NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today upgraded shares of Qiagen to Market Perform, citing the firm's recently acquired Ingenuity business, stabilization in its US human papillomavirus business, and Qiagen's movement toward higher growth businesses.

NEW YORK (GenomeWeb News) – Cowen & Co. today started covering Bruker, giving it an Outperform rating and a $21 price target.

NEW YORK (GenomeWeb News) – Investment bank Cowen & Co. today initiated coverage of molecular diagnostics companies GenMark Diagnostics and Nanosphere with Outperform ratings.

NEW YORK (GenomeWeb News) – Citing a recent run up in Life Technologies' stock fueled by speculation that it may be positioning itself to be bought, investment bank Cowen & Co. today downgraded the Carlsbad, Calif.-based firm to Neutral from Outperform.

NEW YORK (GenomeWeb News) – Investment bank Cowen and Co. has downgraded the stocks of Luminex and Qiagen to Underperform from Neutral.

NEW YORK (GenomeWeb News) – Piper Jaffray today downgraded Cepheid to a Neutral rating from Overweight, saying a manufacturing issue related to its Xpert cartridges could negatively impact fourth-quarter revenues.

Pages

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.